T-Therapeutics Reloads with a $133M Megaround for Bispecifics

T-Therapeutics reloads with a $133M megaround for bispecifics

The startup is built around technology it claims can help get after known, but undruggable cancer targets and design particularly selective autoimmune disease treatments.

T-Therapeutics Raises $133 Million Series B | Cooley // Cooley // Global Law Firm

London – November 5, 2026 – Cooley advised T-Therapeutics, a biotechnology company developing next-generation T cell receptor (TCR) T cell engager (TCE) for cancer and autoimmune diseases, on the closing of an oversubscribed $133 million Series B. The financing was co-led by Advent Life Sciences and British Business Bank with participation from other new investors and all existing major shareholders. Lawyers Tom Goodman, Ellen Dewhurst and Bijal…

T-Therapeutics raises $133M to bring TCR bispecifics into clinic - European Biotechnology Magazine

Cambridge-based T-Therapeutics has raised $133 million (€118 million) in an oversubscribed Series B financing to advance two experimental T-cell engager therapies for cancer and autoimmune diseases into clinical trials. The round brings the University of Cambridge spinout's total Series A and B funding to $224 million.